Boryeong Obtains Approval for Diabetes Combination Improved New Drug 'Trueverdi'..."World's First Combination"

Dapagliflozin·Pioglitazone Combination Therapy

Boryung announced on the 5th that it had obtained the world's first marketing authorization from the Ministry of Food and Drug Safety last month on the 28th for 'Truebuddy,' a combination diabetes complex drug.

Boryeong headquarters exterior.
Photo by Boryeong

Truebuddy is an improved new drug combining dapagliflozin, a sodium-glucose co-transporter (SGLT)-2 inhibitor, and pioglitazone from the TZD (thiazolidinedione) class. The products approved this time are Truebuddy tablets 10/30 mg and Truebuddy tablets 10/15 mg, marking the first case of a combination drug approval for these two components.

Dapagliflozin and pioglitazone are medications used for type 2 diabetes, which accounts for 90% of all diabetes cases. According to the company, both components not only lower blood sugar levels but also produce a synergistic effect when used together by combining the advantages of each component and offsetting side effects.

Specifically, dapagliflozin improves three of the eight factors causing type 2 diabetes: 'impaired insulin secretion in the pancreas,' 'increased glucose reabsorption in the kidneys,' and 'reduced glucose uptake in muscles.' Pioglitazone improves 'impaired insulin secretion in the pancreas,' 'increased glucose production in the liver,' 'reduced glucose uptake in muscles,' and 'reduced glucose uptake in adipose tissue.'

Furthermore, the combination of the two components not only lowers blood sugar but also reduces cardiovascular mortality and enhances effects on myocardial infarction, stroke, kidney disease, and blood pressure reduction. Additionally, the synergy between the two components is expected to improve indicators of non-alcoholic fatty liver disease (NAFLD), insulin sensitivity, and beta-cell function involved in insulin secretion in the pancreas.

The combination can also reduce side effects. TZD class drugs can cause fluid retention (edema) and weight gain, but SGLT-2 inhibitors reduce fluid retention and decrease weight, thereby offsetting these side effects.

Professor Wooje Lee of the Department of Endocrinology at Seoul Asan Medical Center, who led the clinical trials of Truebuddy, said, "The combination of SGLT-2 inhibitors and TZD (thiazolidinedione) class drugs can be an effective combination."

Meanwhile, Boryung plans to expand its market share through intensive investment in the diabetes business and continuous new product launches.

This content was produced with the assistance of AI translation services.